new fda regulations for semaglutide Compounded "semaglutide" is not FDA-approved FDA approves Ozempic® (semaglutide) as

The bioequivalence requirement ensures that the amount of drug reaching your bloodstream and the speed at which it acts are clinically equivalent to Ozempic

Understanding the molecular basis of plant growth promotional effect of Pseudomonas fluorescens on rice through protein profiling

10.3390/jcdd8100130 J Cardiovasc Dev Dis

In July 2024, researchers at Mass Eye and Ear published a landmark study in JAMA Ophthalmology linking semaglutide to a significantly elevated risk of nonarteritic anterior ischemic optic neuropathy (NAION) - a condition that can cause sudden, irreversible partial or total vision loss in one eye